Sichuan Kelun Pharmaceutical (SHE:002422) received approval from the Chinese drug administration for the registration of its rotigotine patch, according to a Saturday disclosure on the Shenzhen bourse.
The Chinese pharmaceutical company's shares jumped less than 4% during Monday's afternoon trade.
The patch, which was first developed by UCB Pharma, is used for the treatment of Parkinson's disease.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments